FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                       
1. Name and Address of Reporting Person * Kummerfeld Keith C 2. Issuer Name and Ticker or Trading Symbol Arcturus Therapeutics Holdings Inc. [ ARCT ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
See Remarks
(Last)          (First)          (Middle)
C/O ARCTURUS THERAPEUTICS HOLDINGS INC., 10628 SCIENCE CENTER DRIVE, SUITE 250		 3. Date of Earliest Transaction (MM/DD/YYYY)
12/9/2022
(Street)
SAN DIEGO, CA 92121
(City)        (State)        (Zip)
 4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
 6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy)  $16.92  12/9/2022    A     40000 (1)      (2) 12/9/2032  Common Stock  40000  $0.00  40000  D   

Explanation of Responses:
(1)  Represents options to purchase shares of common stock approved by the Board of Directors on December 9, 2022 pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.
(2)  The shares underlying this option vest 25% on December 9, 2023, the first anniversary of the date this award was approved by the Board of Directors, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

Remarks:
Vice President of Finance and Corporate Controller

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Kummerfeld Keith C
C/O ARCTURUS THERAPEUTICS HOLDINGS INC.
10628 SCIENCE CENTER DRIVE, SUITE 250
SAN DIEGO, CA 92121

See Remarks

Signatures
/s/ Ilan Katz, attorney-in-fact 12/16/2022
**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Arcturus Therapeutics (NASDAQ:ARCT)
Historical Stock Chart
From Feb 2023 to Mar 2023 Click Here for more Arcturus Therapeutics Charts.
Arcturus Therapeutics (NASDAQ:ARCT)
Historical Stock Chart
From Mar 2022 to Mar 2023 Click Here for more Arcturus Therapeutics Charts.